FULL CATALOGUE

A synthetic peptide composed of 15 amino acids, derived from a naturally occurring gastric protein sequence. One of the most widely referenced peptides in in-vitro research, well-characterised stability profile across experimental models.

A synthetic peptide fragment corresponding to a key functional region of the naturally occurring protein Thymosin Beta-4. Widely used as a laboratory reference material due to its well-characterised actin-binding properties and stable molecular profile.

A 29-amino acid synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH), engineered without the Drug Affinity Complex modification. Designed for short-duration receptor binding studies, allowing researchers to examine acute somatotropic signalling without extended plasma persistence.

A synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH), with non-selective binding affinity across the melanocortin receptor family. A well-characterised reference compound for research into central melanocortin system signalling and neuromodulatory pathway interactions.

Nicotinamide Adenine Dinucleotide; an endogenous dinucleotide coenzyme present across all living cells and central to a broad range of biological processes. Supplied at 500mg as a high-purity laboratory reference standard for metabolic and longevity research programmes.

A stabilised synthetic analog of Growth Hormone-Releasing Factor (GRF), supplied at 5mg as a higher-yield laboratory format. Suited to extended research programmes or multi-arm experimental designs requiring consistent, larger-volume supply of this well-characterised GHRH analog.

A Mitochondrial-Derived Peptide (MDP) encoded within the mitochondrial 12S rRNA gene, composed of 16 amino acids. One of a small class of peptides with mitochondrial genomic origins, attracting growing research interest for its role as a mitochondrial-nuclear signalling mediator.

Quad-peptide research blend combining GHK-Cu, KPV, BPC-157, and TB-500 — four individually well-characterised compounds that have each been independently referenced across distinct but complementary biological signalling pathway research programmes. Supplied as a combined reference material for in-vitro laboratory use.

A synthetic tripeptide (Lysine-Proline-Valine) derived from the C-terminal sequence of alpha-MSH. A compact, well-characterised reference compound used in laboratory research examining intracellular signalling pathways and cytokine biology.

A cyclic synthetic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH), engineered for enhanced receptor binding affinity relative to the native sequence. A well-referenced compound in melanocortin receptor research, with a broad binding profile across the MC receptor family.

A synthetic small-molecule agonist of the Estrogen-Related Receptor (ERR) nuclear receptor family. A newer research tool compound generating significant interest in metabolic biology and mitochondrial research for its ability to activate ERR-mediated transcriptional programmes in controlled experimental models.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide Epithalamin. One of the most studied short peptides in longevity-focused research, with a long publication history examining its interactions with telomerase pathway activity and cellular senescence markers.

A synthetic heptapeptide analog derived from the ACTH(4-7) sequence, with additional C-terminal modification for enhanced stability. A well-characterised neuropeptide reference compound with an extensive preclinical research history examining central nervous system signalling interactions.

A synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin. Designed for enhanced stability relative to the native tuftsin sequence, and well-characterised as a reference compound in research examining GABAergic signalling pathway interactions and central nervous system receptor dynamics.

A multi-peptide research blend formulated for in-vitro investigation of dermal biology and cellular signalling pathways. Each constituent compound has been individually characterised in preclinical research, and the blend is supplied as a combined reference material for laboratory use in skin biology and cellular signalling research programmes.

A multi-peptide research blend formulated for in-vitro investigation of musculoskeletal and connective tissue biology signalling pathways. Constituent compounds have each been independently characterised in preclinical research and are supplied as a combined reference material for laboratory research examining tissue biology and cellular signalling mechanisms.

A naturally occurring copper-binding tripeptide (Glycyl-L-histidyl-L-lysine) supplied at 50mg as a high-volume laboratory reference standard. Intended for extended research programmes or multi-assay panels requiring a consistent batch supply of this well-characterised compound.

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from cerebral venous blood in research models during the 1970s. It has been extensively characterised as a reference compound in studies examining central nervous system peptide signalling, neuromodulatory pathway interactions, and hypothalamic regulatory dynamics. DSIP has been investigated across a wide range of in-vitro and preclinical research contexts, with particular interest in its structural interactions with peptidergic receptor systems. Its nonapeptide sequence and endogenous origin make it a well-referenced compound in neuroscience research literature.

A synthetic mitochondria-targeted tetrapeptide designed to selectively bind cardiolipin on the inner mitochondrial membrane. Engineered for resistance to enzymatic degradation, and well-characterised as a reference compound in research examining mitochondrial bioenergetics and oxidative stress pathway dynamics.

A synthetic decapeptide fragment of the endogenous kisspeptin family, retaining the C-terminal sequence required for receptor activation. Designed to mirror native KISS1R binding activity, and well-characterised as a reference compound in research examining hypothalamic-pituitary-gonadal axis signalling interactions and reproductive endocrine dynamics.

A naturally occurring tripeptide composed of glutamate, cysteine, and glycine, central to endogenous antioxidant defence. Characterised by its unique γ-linked structure conferring resistance to standard peptidase cleavage, and well-characterised as a reference compound in research examining cellular redox balance and oxidative stress pathway dynamics.

A synthetic small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). Designed for high target specificity and oral bioavailability in research settings, and well-characterised as a reference compound in research examining cellular NAD+ metabolism and adipocyte energy pathway dynamics.

A synthetic modified fragment (176-191) of the human growth hormone polypeptide, isolated for its lipolytic activity independent of GH receptor-mediated growth effects. Designed for enhanced stability relative to the native hGH sequence, and well-characterised as a reference compound in research examining lipid metabolism pathway interactions and adipose tissue signalling dynamics.

A naturally occurring copper-binding tripeptide (Glycyl-L-histidyl-L-lysine) supplied at 100mg as a high-volume laboratory reference standard. Intended for extended research programmes or multi-assay panels requiring a consistent batch supply of this well-characterised compound.

A synthetic tripeptide (Lysine-Proline-Valine) derived from the C-terminal sequence of alpha-MSH. A compact, well-characterised reference compound used in laboratory research examining intracellular signalling pathways and cytokine biology.

A synthetic long-acting analogue of Insulin-like Growth Factor-1, engineered with a 13-amino acid N-terminal extension and an arginine substitution at position 3. One of the most widely referenced growth factor peptides in in-vitro research, with a significantly extended functional half-life compared to native IGF-1 due to markedly reduced binding affinity for IGF binding proteins (IGFBPs).

A synthetic pentapeptide and selective growth hormone secretagogue, designed as a ghrelin receptor (GHSR-1a) agonist. Distinguished from earlier growth hormone releasing peptides by its high selectivity — stimulating GH release without significant concurrent effects on cortisol or prolactin in experimental models. Widely used as a reference compound in GH secretagogue research due to its clean pharmacological profile and well-documented receptor binding characteristics.

A synthetic 36-amino acid acylated triagonist peptide with agonist activity at the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. One of the most pharmacologically sophisticated incretin-class peptides studied to date, featuring a C20 fatty acid modification that extends plasma half-life through albumin binding. Extensively referenced in metabolic research literature examining combined incretin receptor signalling, energy homeostasis, and adipose biology in controlled laboratory settings.

A synthetic 39-amino acid acylated dual agonist peptide with activity at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Based on a modified GIP peptide backbone with an Aib² substitution for protease resistance and a C18 fatty diacid modification at Lys²⁶ for extended half-life via albumin binding. The first approved dual incretin receptor agonist in its class, and one of the most extensively published synthetic peptides in metabolic and obesity research.